Immunomedics Inc. Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 7 of 7 Posts
IMMU: Why This Biotech Could Go Crazy In 2019
Article By: TipRanks Tuesday, August 28, 2018 4:30 PM EDT
It’s been a year of rapid-fire growth for IMMU. The stock has rocketed 51% in 2018 alone; and 103% in year-over-year growth. Momentum doesn’t seem to be trailing for the mid-cap company either.
In this article: IMMU Also: CELG
Read
Biotech Stocks Emerge Unscathed And Ready To Go
Article By: Tarun Chandra, CFA Friday, May 18, 2018 8:41 PM EDT
The biotech stocks have been demonstrating strong resilience in the face of intense volatility since February and, remarkably, keeping pace with the broader indexes, considering the highly speculative and volatile nature of the group.
In this article: CVS, MRK, IBB, INCY, ESRX, XBI, ARNA, ECYT, IMMU, IRWD, DVAX, SUPN, SRPT, AGIO, QURE, HRTX, LOXO, ATRA, BGNE, ADAP, CRSP, CBIO, GTHX, MRTX
Read
Immunomedics - Chart Of The Day
Article By: Jim Van Meerten Saturday, August 26, 2017 8:59 AM EDT
Since the Trend Spotter signaled a buy on 8/22 the stock gained 9.61%.
In this article: IMMU
Read
Seattle Genetics Eliminates $2 Billion Deal With Immunomedics
Article By: Terry Chrisomalis Saturday, May 6, 2017 1:39 PM EDT
On Friday, it was announced that Seattle Genetics had ended a potential $2 billion deal with Immunomedics. The initial deal was proposed back in February of this year.
In this article: SGEN, IMMU
Read
Jefferies Sees 'Attractive Buying Opportunities' In Biotech
Article By: The Fly Tuesday, October 18, 2016 10:16 AM EDT
The Jefferies Biotechnology team sees "attractive buying opportunities" amidst the pre-election weakness. They recommend using the weakness to buy select names ahead of a potential improvement in sentiment.
In this article: IMMU, ALKS, CELG, GILD, MDCO, VRTX, CEMP, ALDR, RARE
Read
Immunomedics Announces Closing Of $30 Million Financing
Article By: NASDAQ GlobeNewswire Wednesday, October 12, 2016 3:54 PM EDT
Immunomedics, Inc., announced today that it has closed on a previously disclosed underwritten offering of 10,000,000 shares of common stock and warrants to purchase up to 10,000,000 shares of common stock, with gross proceeds of $30 million.
In this article: IMMU
Read
E Immunomedics Receives FDA Breakthrough Therapy Designation For Breast Cancer Drug
Article By: Terry Chrisomalis Sunday, February 7, 2016 11:24 AM EDT
Breakthrough Therapy Designation gives priority review to the drug in question. That means instead waiting 10 to 12 months for a drug review they only need wait 3 to 4 months after NDA submission.
In this article: IMMU
Read
1 to 7 of 7 Posts